Hearing News Watch

Featured image for “US Air Force Updates Hearing Loss Waiver Policies, Expanding Opportunities for Recruits”
Dec. 31, 2024

US Air Force Updates Hearing Loss Waiver Policies, Expanding Opportunities for Recruits

HHTM
In a significant policy shift, the Department of the Air Force (DAF) has updated its medical waiver guidelines for hearing loss, offering a pathway for more individuals with mild to moderate hearing impairments to serve. This change, part of a broader overhaul that also addresses asthma and food allergies, reflects evolving medical standards and advancements in hearing aid and assistive
Featured image for “Sensorion Completes First Cohort Enrollment for Audiogene Phase 1/2 Hearing Loss Gene Therapy Trial”
Dec. 30, 2024

Sensorion Completes First Cohort Enrollment for Audiogene Phase 1/2 Hearing Loss Gene Therapy Trial

HHTM
MONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat, and prevent hearing loss disorders, today announced the completion of enrollment for the first cohort of its Audiogene Phase 1/2 gene therapy clinical trial. Successful Completion of First Cohort Enrollment Marks Key Milestone Recruitment of the first cohort,
Featured image for “Auditory Brainstem Response: A Potential Biomarker for Age-Related Cognitive Decline”
Dec. 29, 2024

Auditory Brainstem Response: A Potential Biomarker for Age-Related Cognitive Decline

HHTM
For decades, Auditory Brainstem Response (ABR) testing has been a cornerstone in audiology, primarily used for assessing hearing thresholds in infants, difficult-to-test populations, and individuals with suspected auditory nerve or brainstem disorders. By measuring the brain’s electrical responses to sound stimuli, ABR offers an objective, non-invasive assessment of auditory pathway integrity. However, a recent study published in Communications Biology reveals
Featured image for “Study Examines the Link Between Cochlear Implants, Attention, and Memory in Older Adults”
Dec. 28, 2024

Study Examines the Link Between Cochlear Implants, Attention, and Memory in Older Adults

HHTM
A new study published in PLOS ONE investigates how older adults with cochlear implants (CIs) manage attention and memory across auditory and visual tasks. The research, led by Amisha Ojha and colleagues, aims to understand whether hearing restoration through cochlear implants affects cognitive functions such as reflective attention—a process that allows individuals to focus on specific memories or details held
Featured image for “Medicare to End Telehealth Coverage for Audiology in 2025: A Step Backward for Hearing Care Access”
Dec. 27, 2024

Medicare to End Telehealth Coverage for Audiology in 2025: A Step Backward for Hearing Care Access

HHTM
Medicare beneficiaries relying on telehealth services for audiology care may face significant barriers starting January 1, 2025, as the Centers for Medicare & Medicaid Services (CMS) plans to end coverage for these services. An article published this week in JAMA Otolaryngology–Head & Neck Surgery highlights the implications of this decision, which threatens to reverse progress made in improving access to
Featured image for “Top 10 Hearing News Stories of 2024”
Dec. 23, 2024

Top 10 Hearing News Stories of 2024

HHTM
No excerpt
Featured image for “UK Health Authority Endorses Drug to Prevent Pediatric Hearing Loss from Cancer Treatment”
Dec. 21, 2024

UK Health Authority Endorses Drug to Prevent Pediatric Hearing Loss from Cancer Treatment

HHTM
LONDON, UNITED KINGDOM — The National Institute for Health and Care Excellence (NICE) has recommended a new treatment aimed at preventing and reducing hearing loss in patients undergoing cisplatin chemotherapy. This marks a significant step forward in addressing a common and often debilitating side effect of a widely used cancer treatment. Cisplatin is a chemotherapy drug commonly administered to treat various
Featured image for “Sensorion Reports Promising Early Data in Audiogene Gene Therapy Clinical Study in Young Patients”
Dec. 18, 2024

Sensorion Reports Promising Early Data in Audiogene Gene Therapy Clinical Study in Young Patients

HHTM
MONTPELLIER, FRANCE – Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company specializing in therapies to restore, treat, and prevent hearing loss disorders, has announced promising data from the first two patients treated in the Audiogene Phase 1/2 clinical trial evaluating SENS-501. This trial focuses on infants and toddlers aged 6 to 31 months who suffer from a specific form of
Featured image for “Bill Austin Receives Prestigious Honorary Degree from Kenyatta University”
Dec. 16, 2024

Bill Austin Receives Prestigious Honorary Degree from Kenyatta University

HHTM
EDEN PRAIRIE, MINNESOTA – Starkey has announced that its Founder and Chairman, William F. Austin, has been awarded an honorary degree from Kenyatta University in recognition of his groundbreaking contributions to hearing healthcare and his unwavering commitment to serving disadvantaged communities in Africa and throughout the world. Bill Austin’s vision and generosity have touched millions of lives around the globe.
Featured image for “Demant Care Community Champions Respite Home for Women Battling Cancer”
Dec. 16, 2024

Demant Care Community Champions Respite Home for Women Battling Cancer

HHTM
SOMERSET, NEW JERSEY — On December 6th, Oticon President Gary Rosenblum and Mariann Cadieu, Executive Director of the Oticon Hearing Foundation, visited Mary’s Place by the Sea—a respite home dedicated to supporting women battling cancer. The facility received a generous donation raised through the dedicated efforts of Demant staff volunteers and sales promotions. During their visit, the team toured the